Page last updated: 2024-11-04

tegafur and Obesity

tegafur has been researched along with Obesity in 2 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Medroxyprogesterone acetate (MPA) plus Tegafur (TGF) therapy was performed to evaluate the efficacy in a treatment for Tamoxifen- and Adriamycin-resistant advanced breast cancers."7.67[Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. ( Aizawa, M; Houjou, T; Kadota, K; Kurooka, K; Matunami, N; Mori, N; Morikawa, E; Nakano, K; Wada, T; Yamato, M, 1989)
"Medroxyprogesterone acetate (MPA) plus Tegafur (TGF) therapy was performed to evaluate the efficacy in a treatment for Tamoxifen- and Adriamycin-resistant advanced breast cancers."3.67[Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. ( Aizawa, M; Houjou, T; Kadota, K; Kurooka, K; Matunami, N; Mori, N; Morikawa, E; Nakano, K; Wada, T; Yamato, M, 1989)
" However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients."2.50Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'. ( Fujita, K; Sasaki, Y, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujita, K1
Sasaki, Y1
Wada, T1
Matunami, N1
Houjou, T1
Morikawa, E1
Mori, N1
Nakano, K1
Aizawa, M1
Kurooka, K1
Kadota, K1
Yamato, M1

Reviews

1 review available for tegafur and Obesity

ArticleYear
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
    Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:1

    Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationsh

2014

Other Studies

1 other study available for tegafur and Obesity

ArticleYear
[Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:5

    Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Evaluation; Drug Resistance; Drug Therapy, Combinat

1989